Samsung Epis Holdings Reports First Quarter 2026 Financial Results
23.4.2026 08:54:00 CEST | Business Wire | Press Release
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026.
“Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.”
First Quarter 2026 Results
On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion. Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.
First quarter growth surpassed the January 2025 guidance by more than 10%, reflecting stronger-than-expected performance across the business.
Samsung Epis Holdings posted a consolidated revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. Non-cash accounting adjustments, including amortization of purchase price allocation (PPA)-related development costs, are reflected in consolidated revenue and operating profit, following a consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6 billion in November and December 2025.
[Samsung Bioepis Earnings, KRW billion] | ||||
Q1’24 | Q1’25 | Q1’26 | YoY Change | |
Revenue | 280.1 | 400.6 | 454.9 | +54.3 (+14%) |
Operating Profit | 38.1 | 127.9 | 144.0 | +16.1 (+13%) |
Business Updates
- In October 2025, Samsung Bioepis entered into a private label partnership with CVS Caremark, the Pharmacy Benefit Manager (PBM) division of CVS Health, for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1.
- BENEPALI™ (etanercept), Samsung Bioepis’ first biosimilar in Europe, continues to maintain its leadership position in the market as it celebrates its 10th anniversary in Europe.
- In March, Samsung Bioepis expanded its development and commercialization partnership with Sandoz, on up to five biosimilar candidates including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets.
- Also in March, a Phase 1 first-in-human clinical trial for Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate, SBE303, has begun. Following the announcement, the company also presented a poster presentation of its nonclinical data at the American Association for Cancer Research (AACR) 2026 on April 20th which demonstrates its encouraging efficacy, safety, tolerability and a promising ability to work in combination with existing immuno-oncology therapies.
- Samsung Bioepis’s second novel ADC candidate, SBE313, is currently in nonclinical development in collaboration with Phrontline Biopharma.
Disclaimer
This document contains ‘forward-looking statements’ regarding future expectations, projections, plans, and anticipation. ‘Forward-looking statements’ are matters that pertain to the Company’s future business and financial performance, and are subject to uncertainties such as trends in domestic and international financial markets, including but not limited to fluctuations in exchange rates and/or interest rates.
‘Forward-looking statements,’ by their nature, addresses matters that may be uncertain; actual results may be materially different from those expressed in this document.
About Samsung Epis Holdings Co., Ltd.
As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: www.samsungepisholdings.com.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.
About Epis NexLab Co., Ltd.
Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: www.samsungepisholdings.com.
Reference
1 Prolia is a registered trademark of Amgen Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422191520/en/
Contacts
Media Contact
Yoon Kim, yoon1.kim@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press Release
Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues, an increase of 8.2% at constant exchange rates (CER) compared to 2024. EBITDA reached €931 million (25.7%). Chiesi closed 2025 with a positive Net Financial Position (cash minus financial liabilities including leasing) of €729 million, improving by €194 million versus 2024, reconfirming the Group’s capacity to self‑finance its investment strategy. The Group’s three therapeutic areas – Respiratory (Air), Rare Diseases (Rare), and Specialty Care (Care) – all contributed well to the year’s sales. A strong performance in the Global Rare Disease business unit saw sales increase to €906 million, +22.3% at CER, representing 50% of total Group growth across the U.S., Europe and international markets. The Air franchise sales reached €1.886 billion, up 3.9% at
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press Release
The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for the year 2024. The Group net profit was at €250.9 million. In 2024, the corresponding figure was €211.1 million. The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposals formulated by the Board of Directors: Authorization to purch
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press Release
Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP facility lenders tracked has more than doubled since 2024, lender appetite remains concentrated around established managers with scale and predictable managem
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press Release
Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the expansion of the firm’s evergreen offering. The launch of PGIS now cements Pantheon’s global evergreen offerings across private equity, private credit secondaries, and infrastructure secondaries and complements its existing international evergreen suite alongside Pantheon Global Private Equity (PGPE), and Pantheon Global Credit Secondaries Fund (PGCS). PGIS aims to comprise a high-conviction portfolio and is designed to provide professional investors with access to a diversified portfolio of global infrastructure secondaries assets, managed by the firm’s distinguished institutional infrastructure arm. Jérôme Duthu-Bengtzon, Partner and Portfolio Manager of PGIS, said, “The new fund will aim to combine the b
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press Release
KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At present, three major bottlenecks are limiting the ability of AI agents to deliver consistent performance and sustainable ROI: Wasted Capacity: Tradition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom